TECP

Trails Edge Capital Partners Portfolio holdings

AUM $425M
This Fund
S&P 500
This Quarter Est. Return
1 Year Est. Return
–
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$425M
AUM Growth
+$20.2M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
34
New
Increased
Reduced
Closed

Top Buys

1
+$28.4M
2
+$24.7M
3
+$19.1M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$15.2M
5
FDMT icon
4D Molecular Therapeutics
FDMT
+$11.3M

Top Sells

1
+$37.9M
2
+$18.4M
3
+$14.9M
4
APGE icon
Apogee Therapeutics
APGE
+$14.5M
5
DFTX
Definium Therapeutics
DFTX
+$14.1M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRD
26
Opus Genetics
IRD
$337M
$2.27M 0.54%
+500,000
ACAD icon
27
Acadia Pharmaceuticals
ACAD
$3.63B
– –
-1,419,406
APGE icon
28
Apogee Therapeutics
APGE
$5.86B
– –
-192,000
CMPX icon
29
Compass Therapeutics
CMPX
$409M
– –
-1,415,273
ELVN icon
30
Enliven Therapeutics
ELVN
$2.52B
– –
-199,306
FOLD
31
DELISTED
Amicus Therapeutics
FOLD
– –
-1,043,313
TERN
32
DELISTED
Terns Pharmaceuticals
TERN
– –
-300,000
TYRA icon
33
Tyra Biosciences
TYRA
$1.97B
– –
-700,000
MBX
34
MBX Biosciences
MBX
$1.52B
– –
-315,158
1
2